Vaccine News and Research

Latest Vaccine News and Research

PATH malaria vaccine initiative to collaborate with GSK and Crucell in development of 2nd-generation malaria vaccine

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline (GSK). This collaboration is aimed at developing a second-generation vaccine against malaria—a deadly disease that kills close to 800,000 people annually, most of them young children under age five in Africa. MVI drives the development of malaria vaccines by joining its scientific, managerial, and field expertise with companies, universities, and governments to test potential malaria vaccines and invest in those with the most promise.

6 Jun 2011

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

TRION Pharma GmbH has announced that the results from two different studies demonstrate catumaxomab’s capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. The data were obtained by two independent research teams using catumaxomab in malignant ascites and gastric cancer, respectively. The results were recently presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

6 Jun 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

6 Jun 2011

Several drug makers plan to lower prices of vaccines for GAVI purchase

Several pharmaceutical companies have pledged to lower the prices of vaccines against childhood illnesses ahead of the GAVI Alliance conference in London next week, the Guardian reports (Quinn, 6/6).

6 Jun 2011

An anniversary — AIDS turns 30

Three decades after the first cases of AIDS were recorded, more than 60 million people have been infected worldwide. Scientists agree that the epidemic is far from over and, even with major treatment advances and improvement in understanding the illness, hurdles remain in the effort to eradicate the disease.

6 Jun 2011

Bharat Biotech announces the pricing for ROTAVAC vaccine

Bharat Biotech today announced the price of ROTAVAC India’s first indigenously developed Rotavirus Vaccine. The vaccine will be sold to global public markets, Governments worldwide including UN procurement agencies at a price of US $ 1.0. Bharat Biotech hopes its new vaccine will help prevent part of the ~ 500,000 child deaths each year caused due to rotavirus diarrhea and improve access to better, affordable rotavirus vaccines.

6 Jun 2011

Anti-ghrelin vaccine decreases food intake and increases calorie burning in mice

A new therapeutic vaccine to treat obesity by suppressing the appetite-stimulating hormone ghrelin decreases food intake and increases calorie burning in mice, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

GAVI welcomes lower pentavalent vaccine price

In the lead up to its first pledging conference on June 13, the GAVI Alliance announced today it has achieved commitments from two emerging market vaccine manufacturers to lower prices for the life-saving pentavalent vaccine, which protects against five deadly diseases. Developed country manufacturers have also offered price reductions on rotavirus and human papillomavirus, or HPV, vaccines.

5 Jun 2011

Ross River Fever vaccine trials begin

Australian researchers are working on a new vaccine that could protect against mosquito-borne Ross River Fever. They are conducting the world-first trial of the vaccine with positive results reported so far.

5 Jun 2011

Department of Health urges caregivers, parents to update students' immunizations

Parents and caregivers are urged to use the summer break to make sure all students' immunizations are up to date before new regulations take effect in August, the Department of Health said today.

4 Jun 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate.

4 Jun 2011

GW researchers demonstrate Mta1 gene's role in survival of schistosomes

By using mice lacking a crucial gene that controls the process of chromatin remodeling of cytokines including those responsible for inflammation and comparing them to normal wild type mice with the gene, researchers at the George Washington University School of Medicine and Health Sciences have shown that the gene, Mta1, is essential for the parasite Schistosoma haematobium to establish a productive infection and survival in the host.

4 Jun 2011

Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma

For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 can improve response rate and progression-free survival.

4 Jun 2011

Cancer vaccine shows improved response rate in patients

A vaccine for one of the most lethal cancers, advanced melanoma, has improved response rate and progression-free survival for patients when combined with the immunotherapy drug Interleukin-2, according to research led by scientists from The University of Texas MD Anderson Cancer Center and Indiana University Health Goshen Center for Cancer Care.

3 Jun 2011

Lung-sparing surgery, photodynamic therapy improve survival of mesothelioma patients

Pleural mesothelioma patients who undergo lung-sparing surgery in combination with photodynamic therapy (PDT) show superior overall survival than patient treated using the conventional therapy of extrapleural pneumonectomy (EPP) with PDT, indicates new research from the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania.

3 Jun 2011

APC8015F investigational vaccine improves survival of prostate cancer patients

Metastatic prostate cancer patients who received an investigational vaccine made from their own frozen immune cells lived 10 months longer than those not treated with it, according to data being presented by researchers from the Kimmel Cancer Center at Jefferson at the 2011 American Society of Clinical Oncology annual meeting in Chicago on Saturday, June 4.

3 Jun 2011

IMUC, BioWa sign license deal to develop ADCC enhanced antibodies for cancer

ImmunoCellular Therapeutics, Ltd. and BioWa, Inc. today announced that they have entered into a agreement to provide IMUC with access to BioWa's patented POTELLIGENT Technology platform for the development of antibody-dependent cellular cytotoxicity enhanced antibodies.

3 Jun 2011

Positive interim results from iBio's H1N1 influenza subunit vaccine Phase 1 trial

iBio, Inc. today announced positive interim results from a Phase 1 clinical trial of an iBioLaunch platform-produced subunit vaccine directed against Influenza A/California/04/09 (H1N1).

3 Jun 2011

Opinion: Integrate NTD, HIV, TB and malaria programs

In a New England Journal of Medicine opinion piece, Peter Hotez of the Sabin Vaccine Institute and colleagues, including Jeffrey Sachs of the Earth Institute of Columbia University, outline how integrating treatment of neglected tropical diseases (NTD) into HIV/AIDS, tuberculosis and malaria control efforts could speed up progress toward attaining the sixth Millennium Development Goal.

3 Jun 2011

Scientists uncover new therapeutic target that could prevent stress-related cell death

Scientists from the Florida campus of The Scripps Research Institute have uncovered a potentially important new therapeutic target that could prevent stress-related cell death, a characteristic of neurodegenerative diseases such as Parkinson's, as well as heart attack and stroke.

3 Jun 2011

Vaccine News and Research

Latest Vaccine News and Research

PATH malaria vaccine initiative to collaborate with GSK and Crucell in development of 2nd-generation malaria vaccine

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Several drug makers plan to lower prices of vaccines for GAVI purchase

An anniversary — AIDS turns 30

Bharat Biotech announces the pricing for ROTAVAC vaccine

Anti-ghrelin vaccine decreases food intake and increases calorie burning in mice

GAVI welcomes lower pentavalent vaccine price

Ross River Fever vaccine trials begin

Department of Health urges caregivers, parents to update students' immunizations

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

GW researchers demonstrate Mta1 gene's role in survival of schistosomes

Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma

Cancer vaccine shows improved response rate in patients

Lung-sparing surgery, photodynamic therapy improve survival of mesothelioma patients

APC8015F investigational vaccine improves survival of prostate cancer patients

IMUC, BioWa sign license deal to develop ADCC enhanced antibodies for cancer

Positive interim results from iBio's H1N1 influenza subunit vaccine Phase 1 trial

Opinion: Integrate NTD, HIV, TB and malaria programs

Scientists uncover new therapeutic target that could prevent stress-related cell death

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Vaccine News and Research

Latest Vaccine News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in